Compare Linde PLC (LIN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Zimmer Biomet Holdings Inc — how do they compare? Linde PLC trades at $488.01 (market cap $226.12B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.55B). The key difference: Linde PLC is far larger — about 12.2× Zimmer Biomet Holdings Inc's market cap, and Linde PLC pays the higher dividend (1.3%). Which is the better fit depends on your goals.
| LIN | ZBH | |
|---|---|---|
Market Cap | $226.12B | $18.55B |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $107.71 |
52-Week Low | $389.38 | $79.58 |
Enterprise Value | $249.24B | $25.61B |
Dividend Yield | 1.3% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $492.46, up 0.51% on the day, with a bearish technical signal but strong fundamentals. The company reported consistent earnings beats, with Q2 2026 EPS of $4.50 exceeding the $4.49 estimate (Zacks Investment Research, 2026-05-01). Revenue growth is steady, and profitability remains robust with a 20.43% net income margin. Analyst sentiment is overwhelmingly positive, with a consensus price target of $553.60.
The outlook for LIN is favorable due to its operational strength and dividend growth, though valuation multiples are elevated. Key risks include rising debt levels and macroeconomic pressures on industrial demand. The stock offers a compelling opportunity for long-term investors seeking quality industrial exposure, but near-term technical weakness may present entry points.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
